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Objective
To evaluate the impact of components of metabolic syndrome
(MetS) on urinary outcomes after surgery for severe lower
urinary tract symptoms (LUTS) due to benign prostatic
enlargement (BPE), as central obesity can be associated with
the development of BPE and with the worsening of LUTS.
Patients and Methods
A multicentre prospective study was conducted including 378
consecutive men surgically treated for large BPE with simple
open prostatectomy (OP) or transurethral resection of the
prostate (TURP), between January 2012 and October 2013.
LUTS were measured by the International Prostate Symptom
Score (IPSS), immediately before surgery and at 6–12 months
postoperatively. MetS was defined according the USA National
Cholesterol Education Program-Adult Treatment Panel III.
Results
The improvement of total and storage IPSS postoperatively
was related to diastolic blood pressure and waist
circumference (WC). A WC of >102 cm was associated with
a higher risk of an incomplete recovery of both total IPSS
(odds ratio [OR] 0.343, P = 0.001) and storage IPSS (OR
0.208, P < 0.001), as compared with a WC of <102 cm. The
main limitations were: (i) population selected from a tertiary
centre, (ii) Use exclusively of IPSS questionnaire, and (iii) No
inclusion of further data.
Conclusions
Increased WC is associated with persistent postoperative
urinary symptoms after surgical treatment of BPE. Obese
men have a higher risk of persistent storage LUTS after
TURP or OP.
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Introduction
Excess bodyweight has progressively increased since the
1980s, rapidly becoming a worldwide epidemic disorder with
a remarkable socioeconomic impact, due to its association
with increased morbidity and mortality [1].
Central obesity is also considered an early step in the
development and progression of metabolic syndrome (MetS),
a cluster of several medical conditions in addition to
abdominal obesity, including diabetes, dyslipidaemia (high
triglycerides and low high-density lipoprotein [HDL]
cholesterol), autonomic hyperactivity and arterial
hypertension [2]. In particular, visceral adipose tissue secretes
various bioactive substances that can induce inflammatory
responses and have proinflammatory effects. The progressive
development of inflammation in men with MetS may explain
the emerging link between MetS, benign prostatic
enlargement (BPE) and LUTS [3–5].
In 1985, Glynn et al. [6] noted that in the Veterans
Administration Normative Aging Study, only body mass
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index (BMI) was a significant predictor of a clinical diagnosis
of BPH. Giovannucci et al. [7], 20 years ago, described the
association between obesity (measured as waist circumference,
WC) and BPH in a population of men followed for incidence
of prostatectomy, suggesting that central obesity could worsen
urinary symptoms and increase the risk of prostatic surgery.
These data have recently been confirmed in a retrospective
study showing that in patients with a larger WC there was an
enhanced prevalence of MetS components, with the
consequence of worsened voiding function [8].
The aim of the present multicentre prospective study was to
evaluate the impact of the components of MetS on urinary
outcomes after simple open prostatectomy (OP) or TURP for
severe LUTS due to BPE.
Patients and Methods
Between January 2012 and September 2013, 378 consecutive
men treated with simple OP or TURP for large BPE, were
prospectively enrolled in two tertiary referral centres. In both
high-volume referral centres, all patients included in this trial
were managed by surgeons skilled in the diagnosis and
treatment of BPE. The study did not require any deviation of
the Good Clinical Practice and was conducted in accordance
with the principles expressed in the Declaration of Helsinki.
Inclusion criteria were: prostatectomy (TURP or OP) for
moderate-to-severe LUTS due to BPE refractory to medical
treatment, and ability to communicate and comply with study
requirements. Exclusion criteria were: history of preceding
prostate surgery, chronic medication for prostatitis and/or
urinary infection or bladder stone, and known malignant
disease including prostate cancer.
LUTS were measured by the IPSS and categorised as storage
and voiding symptoms, immediately before surgery and at 6–
12 months postoperatively. The total IPSS score was
categorised into 0–7, 8–19, 20–35; storage subscore into 0–5,
6–9 and 10–15; voiding subscore into 0–6, 7–13 and 14–20 as
mild, moderate and severe, respectively. For all IPSS (total,
storage and voiding) the percentage of recovery of urinary
symptoms after the operation (total-, storage- and voiding-Δ
IPSS) was calculated using the following method:
([Preoperative IPSS – Postoperative IPSS]/Preoperative IPSS),
expressed as a percentage: the full recovery of lower urinary
tract function was considered as Δ = 100%.
The PSA level and prostate volume (by ultrasound) were
measured before hospitalisation. OP and TURP were
performed as previously reported [9,10].
MetS Parameters
MetS was defined according the USA National Cholesterol
Education Program (NCEP)-Adult Treatment Panel III,
which requires at least three of the following five
components: central obesity (WC of >102 cm), elevated
triglycerides (≥1.7 mmol/L or 150 mg/dL), elevated blood
pressure (BP ≥130/85 mmHg), elevated fasting glucose
(≥6.1 mmol/L or 110 mg/dL) and reduced HDL cholesterol
(<1.03 mmol/L or 40 mg/dL) [11].
WC and BP were measured by trained personnel using a
standardised protocol. In particular, WC was measured
midway between the lowest rib and the iliac crest, to the
nearest 0.1 cm. Blood samples were drawn in the morning,
after an overnight fast, for determination of blood glucose,
total cholesterol, HDL cholesterol and triglycerides, 7–30 days
preoperatively.
Statistical Analyses
The differences between men with MetS and without MetS
were assessed by unpaired t-test (if normal) or with Mann–
Whitney test (in the remaining cases). The correlations
between all the recorded items and the improvement of
urinary symptoms (total-, storage- and voiding-Δ IPSS) were
calculated by a Spearman correlation analysis; significant data
were included in a multivariate logistic regression analysis.
Moreover, we included significant data in a binary logistic
model to evaluate the odds ratio (OR) based on full recovery
of lower urinary tract function (Δ IPSS = 100%) vs partial
recovery (Δ IPSS <100%). All the analyses were done with
SPSS statistics 17.0 version for windows XP and a P < 0.05
was considered to indicate statistical significance.
Results
In all, 378 unselected consecutive men were recruited in two
tertiary referral centres for surgical treatment of BPE. Overall,
191 patients (50.5%) presented moderate LUTS, while 187
(49.5%) had severe LUTS. According to the IPSS subscores,
53 (14.3%), 211 (55.7%) and 114 (30%) patients presented
with mild, moderate or severe voiding LUTS, respectively. In
addition, 80 (21.2%), 149 (39.4%) and 149 (39.4%) presented
with mild, moderate or severe storage LUTS, respectively.
Preoperative patient’s characteristics, stratified according to
MetS diagnosis, are reported in Table 1. As expected, there
was a significant difference between the population according
to weight and BMI (both P < 0.001). Patients with MetS
showed milder preoperative voiding symptoms and worse
postoperative storage symptoms as compared with those
without MetS (Table 1). In addition, an increasing number of
MetS components resulted in increased postoperative storage
IPSS scores (age-adjusted Wald 1.090, P = 0.009; Fig. 1).
Overall, 220 patients (58.2%) reported a complete recovery of
their lower urinary tract function (total-Δ IPSS 100%), while
the remaining 158 (41.8%) had an incomplete recovery; in
particular, 222 men (58.7%) reported a complete recovery of
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their storage symptoms and 293 (77.5%) of their voiding
symptoms. According to the postoperative IPSS subscores,
355 (93.9%), 20 (5.3%) and three (0.8%) patients had mild,
moderate or severe LUTS, respectively. Categorising for
voiding and storage IPSS, 372 (98.4%) and six (1.6%)
patients, had mild or moderate voiding LUTS, while 350
(92.7%), 13 (3.5%) and 15 (3.8%) patients presented mild,
moderate or severe storage LUTS, respectively. Moreover,
patients with MetS reported a lower recovery in total and
storage IPSS as compared with those without MetS (63.2 vs
81.7, P = 0.015 and 19.6 vs 63.6, P = 0.013, respectively).
Improvements in the total and storage IPSS were related to
WC and diastolic BP (Tables 2 and 3), while improvement in
voiding IPSS was only related to diastolic BP (Table 4), after
adjustment for age, smoking history, PSA level and prostate
volume. These data were confirmed after further adjustment
for the numbers of MetS factors (data not shown).
In the binary logistic model, adjusted for age, smoking
history, PSA level, prostate volume, presence of MetS and
surgical procedure, men with a WC of >102 cm had a higher
risk of an incomplete recovery of lower urinary tract function,
Table 1 Descriptive statistics of population of men included in the study,
stratified according to their MetS profile.
Patients (n = 378) With MetS
(n = 140)
Without MetS
(n = 238)
P
Mean (SD) Mean (SD)
Demographic
Age, years 69.7 (7.4) 68.5 (8.8) 0.187
Weight, kg 81.5 (12.0) 77.3 (8.5) 0.000
Height, m 1.72 (0.1) 1.73 (0.1) 0.136
BMI, kg/m2 27.4 (3.5) 25.7 (2.3) <0.001
Prostate features
Prostate volume, mL 79.1 (42.3) 88.6 (58.2) 0.110
PSA level, ng/mL 2.6 (3.0) 1.9 (1.9) 0.143
Preoperative uroflowmetry
Qmax, mL/s 8.9 (3.5) 8.8 (3.6) 0.905
Qave, mL/s 5.5 (2.4) 5.2 (2.2) 0.438
Voided volume, mL 248 (46.5) 257 (58.3) 0.398
Preoperative IPSS
Total 20.0 (5.7) 20.5 (4.8) 0.454
Voiding 11.1 (4.2) 12.3 (4.1) 0.024
Storage 8.9 (3.7) 8.7 (3.2) 0.603
Postoperative IPSS
Total 2.2 (3.8) 1.5 (3.3) 0.077
Voiding 0.5 (1.7) 0.6 (1.1) 0.413
Storage 2.3 (3.6) 1.3 (2.5) 0.015
Qave, average urinary flow rate; Qmax, maximum urinary flow rate.
Table 2 Multivariate regression analysis adjusted for age, PSA level,
volume, smoking history, to evaluate the impact of number of MetS
parameters and each component on the improvement of total IPSS (total-
Δ IPSS).
IPSS total B (non-standardised
coefficient)
Lower
limit
Upper
limit
P
MetS (0–5) 0.047 0.095 0.001 0.052
WC 0.008 0.013 0.003 0.003
Diastolic BP 0.013 0.022 0.005 0.003
Systolic BP 0.005 0.010 0.000 0.057
Glycaemia 0.000 0.002 0.002 0.955
Triglyceride 0.000 0.002 0.001 0.708
HDL-cholesterol 0.002 0.008 0.004 0.547
Table 3 Multivariate regression analysis adjusted for age, PSA, volume,
smoking history, to evaluate the impact of number of MetS parameters
and each component on the improvement of storage IPSS (storage-Δ
IPSS).
IPSS storage B (non-standardised
coefficient)
Lower
limit
Upper
limit
P
MetS (0–5) 0.130 0.240 0.020 0.021
WC 0.021 0.033 0.009 0.001
Diastolic BP 0.027 0.046 0.008 0.006
Systolic BP 0.010 0.022 0.001 0.074
Glycaemia 0.001 0.005 0.006 0.742
Triglyceride 0.000 0.004 0.003 0.895
HDL-cholesterol 0.005 0.018 0.009 0.518
Table 4 Multivariate regression analysis adjusted for age, PSA, volume,
smoking history, to evaluate the impact of number of MetS parameters
and each component on the improvement of voiding IPSS (voiding-Δ
IPSS).
IPSS voiding B (non-standardised
coefficient)
Lower
limit
Upper
limit
P
MetS (0–5) 0.001 0.03 0.031 0.973
WC 0.003 0.006 0.001 0.112
Diastolic BP 0.009 0.014 0.004 0.001
Systolic BP 0.003 0.006 0.000 0.077
Glycaemia 0.001 0.001 0.002 0.336
Triglyceride 0.000 0.001 0.001 0.962
HDL-cholesterol 0.001 0.005 0.003 0.700
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Fig. 1 The mean and 95% CI of the mean of postoperative IPSS storage
score, stratified according to the number of MetS parameters (age-
adjusted Wald 1.090, P = 0.009).
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measured with total IPSS (OR 0.343, P = 0.018; Fig. 2) and
storage IPSS (OR 0.208, P = 0.002; Fig. 3), as compared with
those with a WC of <102 cm. No MetS parameter could be
identified as a determining factor for full recovery of voiding
function (Fig. 4).
Discussion
Central obesity and MetS are becoming critical topics in
urology due to their global epidemic diffusion and strong
relationship with several urological diseases [12]. In the
‘Multicenter Italian Report on Radical prostatectomy:
Outcome and Research’ (MIRROR) study, based on data
from men treated with radical prostatectomy for prostate
cancer in 25 urological departments across the whole Italian
territory, we have previously shown a significant positive
correlation between WC and post-prostatectomy incontinence
severity; the risk of needing at least two pads/day is 2.5-times
greater in men with a WC of ≥102 cm than those with a WC
of <102 cm [13].
While following 5 667 men in the Prostate Cancer Prevention
Trial placebo arm, investigators noted the predictors for
progression were age, baseline LUTS severity, an elevated
hip–waist ratio, as well as ethnic background. Specifically they
noted the risk of LUTS worsening (defined as 2 points worse
on the IPSS) increased by 4% (P < 0.001) with each
additional year of age. Additional risks for worsening LUTS
were 41% higher for Black (P < 0.03) and Hispanic men (P <
0.06) compared with White men, and for severe LUTS these
increases were 68% (P < 0.01) and 59% (P < 0.03),
respectively. Each 0.05 increase in waist–hip ratio (a measure
Total IPSS
P
0.018 0.343 0.142 0.830
0.414 0.692 0.287 1.672
0.068 2.300 0.942 5.617
0.847 1.098 0.426 2.827
0.162 0.439 0.139 1.390
0.01 0.1 1 10
Elevated WC
Elevated Systolic BP
Elevated Glycemia
Elevated Trigliceride
Reduced HDL-CHOL
OR LL UL
Fig. 2 OR based on full recovery of lower urinary tract function (total-Δ IPSS 100%) vs partial recovery (total-Δ IPSS <100%), as derived from a logistic
regression model adjusted for: Age, PSA level, prostate volume, smoking history, surgical procedure (TURP or OP), presence of MetS. LL, lower limit;
UL, upper limit.
0.01 0.1 1 10
Elevated WC
Elevated Systolic BP
Elevated Glycemia
Elevated Trigliceride
Reduced HDL-CHOL
P OR LL UL
Storage IPSS
0.002 0.208 0.077 0.566
0.480 0.702 0.263 1.873
0.211 1.945 0.686 5.514
0.349 1.636 0.528 5.073
0.389 0.389 0.112 1.348
Fig. 3 OR based on full recovery of lower urinary tract function (storage-Δ IPSS 100%) vs partial recovery (storage-Δ IPSS <100%), as derived from a
logistic regression mode adjusted for: Age, PSA level, prostate volume, smoking history, surgical procedure (TURP or OP), presence of MetS. LL, lower
limit; UL, upper limit.
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of abdominal obesity) was associated with a 10% increased
risk of overall LUTS progression (P < 0.003) and severe
LUTS (P < 0.02). They noted that weight loss might be
helpful for the treatment and prevention of LUTS [14]. A
cohort of men undergoing TURP were noted to have a higher
waist–hip ratio than controls; relative to men in the lowest
waist–hip ratio quartile (<0.856) those in the highest quartile
(>0.923) were at 2.4-fold risk of BPH (OR 2.42, 95% CI 1.34–
4.37, test for trend P = 0.01) [15].
Recently, several studies have focused on the impact of MetS
parameters on LUTS due to BPE [15–17]. We have recently
shown that MetS can lead to an increase in prostate volume.
In particular, our meta-regression analysis showed that the
overall prostate volume and the transitional zone increment
were significantly greater in older and obese men, and in
those with low serum HDL cholesterol levels [18].
Moreover, as reported by Lee et al. [8], an increased WC was
associated with worsened voiding function. In particular, the
multivariate logistic regression analysis of urological
parameters with WC showed that as WC increased from <90
to 90–99 to ≥100 cm, there was a greater likelihood for
prostate volume growth (OR 1.39, P = 0.01).
In the present study, we report a unique finding, where the
worse outcomes after surgery for BPH/LUTS were in men
with increased WC. Men with a WC of ≥102 cm had three-
fold risk of an incomplete recovery of LUTS and a five-fold
risk of having persistent storage symptoms after surgery. In
our unselected consecutive cross-sectional population, men
with MetS presented similar baseline IPSS storage scores (8.9
vs 8.7) as compared with men without MetS: nevertheless,
postoperatively they presented significantly worse IPSS
storage scores than those without MetS (2.3 vs 1.3). A
comparable correlation between the number of components
of MetS and the severity of urinary symptoms has been
recently reported in a prospective cross-sectional study of
men aged 50–59 years who had participated in a hospital
health examination [19]. The authors reported that the
number of men with LUTS (IPSS >7), enlarged prostate
volume (total prostate volume ≥30 mL) and/or reduced
maximum urinary flow rate (Qmax < 15 mL/s) significantly
increased with an increasing number of metabolic
abnormalities. These results corroborated our preclinical data,
suggesting that MetS could have a detrimental effect on
prostate health, boosting inflammation, and finally inducing
the concomitant enlargement of the prostatic gland and the
decline of storage LUTS [20].
We recently suggested that hormonal, inflammatory and
metabolic derangements might have a permissive or causative
role in determining BPH. In particular, MetS could induce or
maintain an inflammatory state within the prostate that could
even be exacerbated by a relative hyperoestrogenism [21] or
by androgen deficiency [22,23], medical conditions often
associated to MetS and in particular to increased WC [24,25].
In the present study, diastolic BP emerges as a negative
predictive factor for both voiding and storage urinary
symptoms, while WC seems to have a negative impact
exclusively on storage symptoms (Tables 2, 3 and 4).
Interestingly, these data are consistent to those reported in a
recently published observational study on police officers in
their 50s with moderate-to-severe LUTS (IPSS >7) [26]. Their
logistic regression analysis showed that only WC and
hypertension among the MetS components were determinants
of progression of BPH (OR 1.034, P = 0.021 and OR 1.511, P
= 0.009, respectively). Moreover, the clinical impact of BP on
persistent storage LUTS after TURP has been recently
highlighted by a prospective study on patients treated with
TURP for BOO due to BPH, based on the use of pulsed wave
colour Doppler ultrasonography. The author showed that
0.01 0.1 1 10
P OR LL UL
Elevated WC
Elevated Systolic BP
Elevated Glycemia
Elevated Trigliceride
Reduced HDL-CHOL
0.594 0.758 0.274 2.096
Voiding IPSS
0.676 0.779 0.241 2.518
0.802 1.173 0.336 4.091
0.056 0.290 0.081 1.033
0.312 0.495 0.126 1.936
Fig. 4 OR based on full recovery of lower urinary tract function (voiding-Δ IPSS 100%) vs partial recovery (voiding-Δ IPSS <100%), as derived from a logistic
regression mode adjusted for: Age, PSA level, prostate volume, smoking history, surgical procedure (TURP or OP), presence of MetS. LL, lower limit; UL,
upper limit.
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persistent detrusor overactivity, 1 year after TURP, was
associated with increased vascular resistance of the bladder
vessels with subsequent reduced perfusion and hypoxia [27].
We recently showed in an experimental animal model of high
fat diet-induced MetS, that MetS was associated with severe
vascular damage in the whole of the LUT. In particular, we
observed severe inflammation, running in parallel with
hypoxia and tissue remodelling, both in prostatic and bladder
tissue [22,28].
The binary logistic model showed that in cases of severe
LUTS due to large BPE, the full recovery of LUTS and
especially that of storage symptoms, can be more easily
achieved in men with a WC of <102 cm compared with
those with WC of ≥102 cm. Moreover, central obesity, as
with other MetS parameters, seems to have no detrimental
effect on the recovery of voiding activity, as measured by the
IPSS. Thus surgical removal of central adenomatous tissue
allows one to largely reverse flow-related symptoms,
regardless of MetS features.
Our present prospective study has several limitations. We
included men treated exclusively in tertiary referral centres
for BPE surgery; this population of men with large prostates
(≥80 mL), and a pronounced reduction in urinary flow (Qmax
<9 mL/s) may be very different to that of the general
community. Furthermore, we evaluated the population
exclusively with the IPSS. The use of other validated
questionnaires, such as the Short Form-12 to evaluate overall
health (including physical and mental health), might have
provided additional insight. Moreover, data from preoperative
and postoperative pressure/flow studies were not available.
Finally, we did not adjust our present data for additional
parameters, such as physical activity and comorbidities, which
can influence the development of LUTS or alter clinical
outcomes after any surgical procedure.
In conclusion, our present study demonstrated that increased
WC is associated with worse urinary symptoms recovery after
surgical treatment of BPE. In particular, obese men have a
higher risk of persistent storage LUTS after TURP or OP.
Further prospective studies are needed to confirm our present
data.
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